Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Asthma Clinical Trial

Official title:

A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01857323
• Other study ID #: ABS-AS-308
• Status: Completed
• Phase: Phase 3
• First received: May 15, 2013
• Last updated: May 19, 2015
• Start date: May 2013
• Est. completion date: September 2013

Study information

• Verified date: May 2015
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open-label, multicenter Phase 3 study evaluating the performance of the Albuterol Spiromax dose counter in patients with a diagnosis of asthma and/or COPD. The purpose of this study is to evaluate the functionality, reliability, and accuracy of the Albuterol Spiromax inhaler integrated dose counter in a clinical setting.

Description:

The study consists of a screening/run-in period where, after meeting study criteria, patients enter a run-in period lasting 7 to 14 ±2 days, during which diary and medication compliance, as well as inhaler technique, will be assessed. The run-in period will commence the day following the completion of all screening procedures and will continue through to and include the day prior to the first treatment visit (TV1) such that a minimum of 7 full days of diary data will be collected prior to TV1. The purpose of the run-in period is to assess compliance with a BID dosing regimen and with the completion of the diary entries over a minimum period of 7 days. Patients who demonstrate adequate inhaler technique and who are at least 90% compliant with dosing and completion of the diary on the last 7 consecutive days of run-in will qualify for enrollment into the open-label study. The study treatment period will comprise 6 treatment visits (TV1-TV6) for all enrolled patients except those in the 5-week treatment cohort who will have only 5 treatment visits (TV1-TV5). Patients may continue taking their current asthma or COPD medications throughout the Treatment Period. The patient will return to the clinic on Days 8 (±1), 15 (±1), 22 (±1), and 36 (±1), and then on Day 50 (-2) after approximately all 200 doses have been delivered, or until early withdrawal. The patient will be deemed to have completed the study if at least 90% of the recommended doses contained in Albuterol Spiromax with dose-counter were used. A representative sample (approximately 15%) of patients will participate in the trial for approximately 5 weeks with Day 36 (±1) being the final study visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 317
• Est. completion date: September 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 4 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent/assent signed and dated by the patient and/or parent/legal guardian before conducting any study related procedure

2. Male or female (non pregnant/non lactating) patients 4 years of age or older at the time of the screening visit (SV) who are able to understand English

3. Females of childbearing potential (as judged by the investigator) currently using and will continue to use a medically reliable method of contraception for the entire study duration (e.g. oral, injectable, trans-cutaneous or implantable contraceptives or intrauterine devices or double-barrier protection). Females who are not sexually active must agree to use a medically reliable method of contraception should they become active during the course of the study. Women of childbearing potential, or less than 1 year postmenopausal, will require a negative urine pregnancy test at the SV. Female patients will be considered to be of non-child-bearing potential and will not require a urine pregnancy test if at least one of the following apply:a. before menarche; b. more than one year post-menopausal; c. had a hysterectomy, bilateral oophorectomy, salpingectomy, or tubal ligation; d. has congenital sterility

4. General good health, defined as free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study

5. Has a physician diagnosis of asthma or COPD with symptoms of bronchoconstriction requiring the use of short-acting ß2-agonists

6. Current Therapy: The patient's current asthma/COPD controller treatment regimen has remained stable for at least four weeks prior to the SV

7. Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements (visits, record keeping, etc)

8. Able to demonstrate satisfactory Spiromax inhaler use and technique.

Exclusion Criteria:

1. History of life-threatening asthma or COPD that is defined for this protocol as an asthma or COPD episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures

2. Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of the SV; or that occurs between the SV and TV1

3. Is being treated with a long-acting ß2-agonist alone

4. Any asthma exacerbation requiring oral corticosteroids within 2 months of SV and any COPD exacerbation requiring oral corticosteroids within 1 month of the SV. A patient must not have been hospitalized for asthma or COPD within 4 months prior to the SV.

5. Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular (e.g., congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease, cerebrovascular accident), hepatic, renal, hematological, neuropsychological, endocrine (e.g., uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), and/or gastrointestinal (e.g., poorly-controlled peptic ulcer or gastroesophageal reflux disease [GERD]). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the patient at risk through participation, or which could affect the endpoint analysis if the disease/condition exacerbated during the study.

6. Uncontrolled hypertension (systolic blood pressure [BP] =160 mmHg or diastolic BP >100 mmHg)

7. History of any adverse reaction, including immediate or delayed hypersensitivity to any ß2-agonist, sympathomimetic drug, or any component of the Albuterol Spiromax DPI or rescue ProAir Hydrofluoroalkane (HFA) Metered-dose inhaler (MDI) formulation.

8. Other exclusion criteria apply.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Albuterol Spiromax®
Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.

Locations

Country	Name	City	State
United States	Teva Investigational Site 10636	Bethesda	Maryland
United States	Teva Investigational Site 10642	Bozeman	Montana
United States	Teva Investigational Site 10618	Canton	Ohio
United States	Teva Investigational Site 10622	Centennial	Colorado
United States	Teva Investigational Site 10639	Charleston	South Carolina
United States	Teva Investigational Site 10637	Costa Mesa	California
United States	Teva Investigational Site 10630	Dallas	Texas
United States	Teva Investigational Site 10634	Denver	Colorado
United States	Teva Investigational Site 10625	Eugene	Oregon
United States	Teva Investigational Site 10613	High Point	North Carolina
United States	Teva Investigational Site 10635	Huntington Beach	California
United States	Teva Investigational Site 10626	Medford	Oregon
United States	Teva Investigational Site 10633	Miami	Florida
United States	Teva Investigational Site 10623	New Braunfels	Texas
United States	Teva Investigational Site 10631	North Dartmouth	Massachusetts
United States	Teva Investigational Site 10615	Oklahoma City	Oklahoma
United States	Teva Investigational Site 10640	Ormond Beach	Florida
United States	Teva Investigational Site 10641	Overland Park	Kansas
United States	Teva Investigational Site 10620	Phoenix	Arizona
United States	Teva Investigational Site 10646	Plymouth	Minnesota
United States	Teva Investigational Site 10632	Portland	Oregon
United States	Teva Investigational Site 10616	Raleigh	North Carolina
United States	Teva Investigational Site 10647	Rolling Hills Estates	California
United States	Teva Investigational Site 10638	San Antonio	Texas
United States	Teva Investigational Site 10643	San Diego	California
United States	Teva Investigational Site 10644	San Jose	California
United States	Teva Investigational Site 10617	Spartanburg	South Carolina
United States	Teva Investigational Site 10627	St. Louis	Missouri
United States	Teva Investigational Site 10624	Tulsa	Oklahoma
United States	Teva Investigational Site 10645	Wheat Ridge	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
Teva Pharmaceutical Industries

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Not Count	The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures how often the dose cycle was not counted: the participant completes a full dose cycle (opens the mouthpiece cap, inhales the medication, and closes the mouthpiece cap) but the counter display does not advance (i.e., does not count down) within a dosing session. The discrepancy rate was calculated as "number of discrepancies/total number of dose cycles" *200.	Day 1 - Day 50	No
Secondary	Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Count Up	The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter reading increases, instead of decreases, after the participant has executed the dose cycle (i.e., the ending counter reading is greater than the beginning counter reading within a dosing session). The discrepancy rate was calculated as "number of discrepancies/total number of dose cycles" *200.	Day 1 - Day 50	No
Secondary	Dosing Discrepancies Per 200 Dose Cycles: Count Unknown Dose Cycle	The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter advances (decreases, e.g., 50 to 48) between dosing sessions but the participant has not knowingly executed the dose cycle (i.e., the counter number at the beginning of the dosing session is less than the counter number at the end of the previous dosing session). The discrepancy rate was calculated as "number of discrepancies/total number of dose cycles" *200.	Day 1 - Day 50	No
Secondary	Dosing Discrepancies Per 200 Dose Cycles: Count Up Unknown Dose Cycle	The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter counts upwards (number increases, e.g. 50 to 52) rather than downward between dosing sessions but the participant has not knowingly executed the dose cycle (i.e., the counter number at the beginning of the dosing session is greater than the counter number at the end of the previous dosing session). The discrepancy rate was calculated as "number of discrepancies/total number of dose cycles" *200.	Day 1 - Day 50	No
Secondary	Absolute Value of Total Discrepancy Size Per Inhaler	The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome is calculated for each inhaler as "beginning counter reading minus end counter reading" minus "patient-recorded number of dose cycles". The total inhaler discrepancy size is an important measure because it provides the most relevant means of ensuring that the inhaler does not exhaust its supply of albuterol before the counter has recorded the labeled 200 doses.	Day 1 - Day 50	No
Secondary	Participants With Treatment-Emergent Adverse Events	Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.	Day 1 to Day 50	Yes